Current Medical Science

, Volume 38, Issue 5, pp 853–860 | Cite as

MIF May Participate in Pathogenesis of Polycystic Ovary Syndrome in Rats through MAPK Signalling Pathway

  • Dan-ni Zhou
  • Sai-jiao Li
  • Jin-li Ding
  • Tai-lang Yin
  • Jing YangEmail author
  • Hong YeEmail author


The polycystic ovary syndrome (PCOS) model was established in rats and correlation between the expression of macrophage migration inhibitory factor (MIF) and cytokinesis with the MAPK signalling pathway in the rat ovary was measured. The PCOS model in rats was established by dehydroepiandrosterone (DHEA). Thirty sexually immature female Sprague-Dawley rats were randomly and equally assigned to three groups: control group, PCOS group, and PCOS with high-fat diet (HFD) group. Serum hormones were assayed by radioimmunoassay (RIA). The ovaries were immunohistochemically stained with MIF, and the expression of MIF, p-JNK and p-p38 was detected by Western blotting in ovaries. The serum testosterone level, LH concentration, LH/FSH ratio, fasting insulin level and HOMA IR index in the PCOS group (6.077±0.478, 13.809±1.701, 1.820±0.404, 10.83±1.123 and 1.8692±0.1096) and PCOS with HFD group (6.075±0.439, 14.075±1.927, 1.779±0.277, 10.20±1.377 and 1.7736±0.6851) were significantly higher than those in the control group (4.949±0.337, 2.458±0.509, 1.239±0.038, 9.53±0.548 and 1.5329±0.7363), but there was no significant difference between the PCOS group and PCOS with HFD group. The expression levels of MIF, p-JNK, and p-p38 in the PCOS group (0.4048±0.013, 0.6233±0.093 and 0.7987±0.061) and PCOS with HFD group (0.1929±0.012, 0.3346±0.103 and 0.3468±0.031) were obviously higher than those in control group (0.2492±0.013, 0.3271±0.093 and 0.3393±0.061), but no significant difference was observed between PCOS group and PCOS with HFD group. It was suggested that MIF may participate in the pathogenesis of PCOS through the MAPK signalling pathway in PCOS rats induced by DHEA.

Key words

polycystic ovary syndrome high-fat diet dehydroepiandrosterone migration inhibitory factor MAPK signalling pathway rats 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Morrison MC, Kleemann R. Role of macrophage migration inhibitory factor in obesity, insulin resistance, type 2 diabetes, and associated hepatic comorbidities: a comprehensive review of human and rodent studies. Front Immunol, 2015,6:308Google Scholar
  2. 2.
    Zabuliene L, Tutkuviene J. Body composition and polycystic ovary syndrome. Medicina (Kaunas, Lithuania), 2010,46(2):142Google Scholar
  3. 3.
    Seli E, Duleba AJ. Optimizing ovulation induction in women with polycystic ovary syndrome. Curr Opin Obstet Gynecol, 2002,14(3):245–254Google Scholar
  4. 4.
    González F, Kirwan J, Rote N, et al. Glucose and lipopolysaccharide regulate proatherogenic cytokine release from mononuclear cells in polycystic ovary syndrome. J Reprod Immunol, 2014,103(6):38–44Google Scholar
  5. 5.
    Phelan N, O' Connor A, Tun TK, et al. Leucocytosis in women with polycystic ovary syndrome (PCOS) is incompletely explained by obesity and insulin resistance. Clin Endocrinol, 2012,78(1):107–113Google Scholar
  6. 6.
    Hyejin L, Jee-Young O, Yeon-Ah S, et al. Is insulin resistance an intrinsic defect in asian polycystic ovary syndrome? Yonsei Med J, 2013,54(3):609–614Google Scholar
  7. 7.
    Un Ju J, Myung-Sook C. Obesity and Its Metabolic Complications: The Role of Adipokines and the Relationship between Obesity, Inflammation, Insulin Resistance, Dyslipidemia and Nonalcoholic Fatty Liver Disease. Int J Mol Sci, 2014,15(4):6184–6223Google Scholar
  8. 8.
    Bennett B, Bloom BR. Studies on the migration inhibitory factor associated with delayed-type hypersensivity: cytodynamics and specificity. Transplantation, 1967,5(4):Suppl:996–1000Google Scholar
  9. 9.
    Javeed A, Zhao Y. Macrophage-migration inhibitory factor: role in inflammatory diseases and graft rejection. Inflamm Res, 2008,57(2):45–50Google Scholar
  10. 10.
    Hiroki M, Wataru I, Kazunori T, et al. Augmented reduction of islet β-cell mass in Goto-Kakizaki rats fed high-fat diet and its suppression by pitavastatin treatment. J Diabetes Investig, 2012,3(3):235–244Google Scholar
  11. 11.
    Kleemann R, Kapurniotu A, Frank RW, et al. Disulfide analysis reveals a role for macrophage migration inhibitory factor (MIF) as thiol-protein oxidoreductase. J Mol Biol, 1998,280(1):85–102Google Scholar
  12. 12.
    Terrazas CA, Huitron E, Vazquez A, et al. MIF synergizes with Trypanosoma cruzi antigens to promote efficient dendritic cell maturation and IL-12 production via p38 MAPK. Int J Biol Sci, 2010,7(9):1298–1310Google Scholar
  13. 13.
    Fan H, Hall P, Santos LL, et al. Macrophage migration inhibitory factor and CD74 regulate macrophage chemotactic responses via MAPK and Rho GTPase. J Immunol, 2011,186(8):4915–4924Google Scholar
  14. 14.
    Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science, 2002,298(5600):1911–1912Google Scholar
  15. 15.
    Roux PP, Blenis J. ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiol Mol Biol Rev, 2004,68(2):320–344Google Scholar
  16. 16.
    Lai CF, Chaudhary L, Fausto A, et al. Erk is essential for growth, differentiation, integrin expression, and cell function in human osteoblastic cells. J Biol Chem, 2001,276(17):14 443–14 450Google Scholar
  17. 17.
    Deschênes-Simard X, Kottakis F, Meloche S, et al. ERKs in cancer: friends or foes? Cancer Res, 2014,74(2):412–419Google Scholar
  18. 18.
    Zeke A, Misheva M, Reményi A, et al. JNK Signaling: Regulation and Functions Based on Complex Protein-Protein Partnerships. Microbiol Mol Biol Rev, 2016,80(3):793–835Google Scholar
  19. 19.
    Wilmer WA, Dixon CL, Hebert C. Chronic exposure of human mesangial cells to high glucose environments activates the p38 MAPK pathway. Kidney Int, 2001,60(3):858–871Google Scholar
  20. 20.
    Sumara G, Formentini I, Collins S, et al. Regulation of PKD by the MAPK p38delta in insulin secretion and glucose homeostasis. Cell, 2009,136(2):235–248Google Scholar
  21. 21.
    Lenarcik A, Bidzińska-Speichert B, Tworowska-Bardzińska U, et al. Hormonal abnormalities in firstdegree relatives of women with polycystic ovary syndrome (PCOS). Endokrynol Pol, 2011,62(2):129–133Google Scholar
  22. 22.
    Rosenfield RL, Monica M, Kristen W, et al. Determination of the source of androgen excess in functionally atypical polycystic ovary syndrome by a short dexamethasone androgen-suppression test and a low-dose ACTH test. Hum Reprod, 2011,26(11):3138–3146Google Scholar
  23. 23.
    Lee MT, Anderson E, Lee GY. Changes in ovarian morphology and serum hormones in the rat after treatment with dehydroepiandrosterone. Anat Rec, 1991,231(2):185–192Google Scholar
  24. 24.
    Wang YX, Xie XM, Zhu WJ. Serum adiponectin and resistin levels in patients with polycystic ovarian syndrome and their clinical implications. J Huazhong Univ Sci Technol Med Sci, 2010,30(5):638–642Google Scholar
  25. 25.
    Bach JP, Deuster O, BalzerGeldsetzer M, et al. The role of macrophage inhibitory factor in tumorigenesis and central nervous system tumors. Cancer, 2009,115(10):2031–2040Google Scholar
  26. 26.
    Kleemann R, Bucala R, Kleemann R, et al. Macrophage migration inhibitory factor: critical role in obesity, insulin resistance, and associated comorbidities. Mediators Inflamm, 2010,84(1):111–116Google Scholar
  27. 27.
    Pedro GM, María Pilar M, José Alfredo M, et al. Differential Proinflammatory and Oxidative Stress Response and Vulnerability to Metabolic Syndrome in Habitual High-Fat Young Male Consumers Putatively Predisposed by Their Genetic Background. Int J Mol Sci, 2013,14(9):17 238–17 255Google Scholar
  28. 28.
    Legro RSV, Daniel C, Kauffman RP. Detecting insulin resistance in polycystic ovary syndrome: purposes and pitfalls. Obstet Gynecol Survey, 2004,59(2):141–154Google Scholar
  29. 29.
    Ollila MM, Piltonen T, Puukka K, et al. Weight Gain and Dyslipidemia in Early Adulthood Associate with Polycystic Ovary Syndrome: Prospective Cohort Study. J Clin Endocrinol Metab, 2016,101(2):739–747Google Scholar
  30. 30.
    Frank G, Rote NS, Judi M, et al. Elevated circulating levels of macrophage migration inhibitory factor in polycystic ovary syndrome. Cytokine, 2010, 51(3):240–244Google Scholar
  31. 31.
    Jorly MM,Melchor ÁM, Eduardo RV, et al. Macrophage migration inhibitory factor in obese and non-obese women with polycystic ovary syndrome. Endocrinol Nutr, 2014,62(1):31–37Google Scholar
  32. 32.
    Vossler MR, Yao H, York RD, et al. cAMP activates MAP kinase and Elk-1 through a B-Raf-and Rap1-dependent pathway. Cell, 1997,89(1):73–82Google Scholar
  33. 33.
    Nelson-Degrave VL, Wickenheisser JK, Hendricks KL, et al. Alterations in mitogen-activated protein kinase kinase and extracellular regulated kinase signaling in theca cells contribute to excessive androgen production in polycystic ovary syndrome. Mol Endocrinol, 2005,19(2):379–390Google Scholar
  34. 34.
    Lan CW, Chen MJ, Tai KY, et al. Functional microarray analysis of differentially expressed genes in granulosa cells from women with polycystic ovary syndrome related to MAPK/ERK signaling. Sci Rep, 2015,5:14 994Google Scholar
  35. 35.
    Takahashi K, Koga K, Linge HM, et al. Macrophage CD74 contributes to MIF-induced pulmonary inflammation. Resp Res, 2009,10(1):1–14Google Scholar
  36. 36.
    Lue H, Kapurniotu A, Fingerle-Rowson G, et al. Rapid and transient activation of the ERK MAPK signalling pathway by macrophage migration inhibitory factor (MIF) and dependence on JAB1/CSN5 and Src kinase activity. Cell Signal, 2006,18(5):688–703Google Scholar
  37. 37.
    Zernecke A, Bernhagen J, Weber C. Macrophage migration inhibitory factor in cardiovascular disease. Circulation, 2008,117(12):1594–1602Google Scholar

Copyright information

© Huazhong University of Science and Technology 2018

Authors and Affiliations

  1. 1.Chongqing Institute of Reproduction and GeneticsChongqing Health Center for Women and ChildrenChongqingChina
  2. 2.Reproductive Medical Center, Hubei Clinic Research Center for Assisted Reproductive Technology and Embryonic DevelopmentRenmin Hospital of Wuhan UniversityWuhanChina

Personalised recommendations